In brief
Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease.
In its first initiative under this strategy, the company is advancing a novel long-duration, dual-acting siRNA programme targeting PCSK9 and lipoprotein(a) [Lp(a)], two genetically driven and clinically validated risk factors for cardiovascular disease.
‘ Este Articulo puede contener información publicada por terceros, algunos detalles de este articulo fueron extraídos de la siguiente fuente: www.proactiveinvestors.com.au ’
ADVERTISEMENT
